4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Usher Syndrome by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 7 ongoing clinical trials involving Usher Syndrome
Of the 7 trials,6 trials are in Phase I/II
Furthermore, 1 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Usher Syndrome by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Usher Syndrome, a Genetic Disorders. The largest number of ongoing clinical trials for Usher Syndrome is conducted in Europe. North America and South and Central America are among some of the other prominent regions engaged in Usher Syndrome-related drug trials.

ProQR Therapeutics NV: The leading ongoing Usher Syndrome related clinical trial sponsor

ProQR Therapeutics NV is the top sponsor for Usher Syndrome-related ongoing clinical trials.

Nacuity Pharmaceuticals Inc and Fondazione Telethon are among other notable clinical trial sponsors involved in Usher Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Usher Syndrome

Betamethasone sodium phosphate and Hydrocortisone (Saxizon) are among the key marketed drugs involving Usher Syndrome.

Betamethasone sodium phosphate is a corticosteroid, anti-inflammatory drug and an immunosuppressive agent. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. Betamethasone sodium phosphate is formulated as solution for intravenous and intramuscular route of administration. Betamethasone sodium phosphate was first approved in 1996 and is marketed solely in South Korea by Medica Korea Corp.

Hydrocortisone (Saxizon) is a corticosteroid which belongs to the class of anti-inflammatory agents. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. Hydrocortisone is formulated as powder for solution for intravenous, intramuscular, epidural, intrathecal, intravenous drip, and intraarticular route of administration. Hydrocortisone was first approved in 1970 and is marketed solely in Japan by Kowa Co Ltd.